NAKA

Business Context and Reporting Period

Company: Kindly MD, Inc. (Note: Input metadata referenced "Nakamoto Inc.", but the filing text identifies the registrant as Kindly MD, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period: Three months ended March 31, 2025
Business Overview: Kindly MD is a patient-first healthcare and data company focused on value-based care, reducing opioid use, and integrating mental health with alternative medicine. Services include outpatient and telemedicine evaluation, pain management, and medically managed weight loss. The company is a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased by $249,374 (30.1%) to $579,655. This was primarily due to a decrease in cash-pay patient care services, despite a 145.6% increase in insurance reimbursements ($85,273 in Q1 2025 vs. $34,772 in Q1 2024).
• Operating Expenses Surge: Total operating expenses increased by $555,240 (52.1%) to $1,621,396.
  • Salaries and Wages: Increased $295,211 (41.7%) due to expanded staffing for medical services and public company support.
  • General and Administrative: Increased $302,309 (104.2%) driven by professional fees, D&O insurance, and marketing.
  • R&D: Decreased significantly from $35,417 to $97.
• Net Loss Expansion: Net loss widened to $1,038,011 from $282,326. Loss per share increased 183.3% to $(0.17).
• Interest Expense Reduction: Interest expense dropped by $50,909 (88.9%) to $6,330, attributed to reduced notes payable and amortization of debt discounts.
• Cash Flow: Net cash used in operating activities increased to $865,083 from $213,439. Cash reserves decreased by $1.13 million during the quarter.

Guidance, Outlook, and Risks

• Strategic Shift: Management is shifting focus from cash-pay services to insurance billing with commercial and governmental payers (Medicare, Medicaid, Blue Cross Blue Shield, Cigna, etc.).
• Liquidity Outlook: The company holds $1.14 million in cash. Management states the June 2024 IPO proceeds ($5.86 million net) provide liquidity for at least 12 months. However, working capital decreased, and the company is focused on increasing cash reserves through strategic transactions.
• Capital Needs: The filing explicitly states that the ability to raise capital is necessary to sustain operations and implement the business plan.
• Internal Controls: Management concluded that internal control over financial reporting was not effective as of December 31, 2024, due to material weaknesses. Remediation plans are underway, including engaging consultants and documenting policies.
• Risks: Key risks include the lack of diversification, general market volatility, and the company's reliance on future capital raises to survive.
• Subsequent Events: No material subsequent events were identified. A warrant agent agreement addendum was executed on May 6, 2025.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $1.14 million cash balance given the $865,000 quarterly operating cash burn.
• Revenue Mix Transition: Monitor the success of the shift from cash-pay to insurance billing to offset the 30% revenue decline.
• Internal Control Remediation: Track progress on fixing material weaknesses in financial reporting controls.
• Debt Obligations: Review the maturity schedule for the remaining $64,370 in notes payable due in 2025.
• Stock Repurchases: Note the company repurchased 7,500 shares in Q1 2025 under a $500,000 program, with approximately $490,443 remaining available.